Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa inhibitors are still needed. Ticagrelor and eptifibat...

Full description

Bibliographic Details
Main Authors: Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar
Format: Article
Language:English
Published: Wiley 2017-11-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
antiplatelet therapy
eptifibatide
inhibition of platelet aggregation
ticagrelor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.117.005562

Similar Items

Similar Items